Adamantane - a lead structure for drugs in clinical practice
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F16%3A43915056" target="_blank" >RIV/00023752:_____/16:43915056 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/60162694:G44__/16:43875645 RIV/00179906:_____/16:10329098
Výsledek na webu
<a href="http://www.eurekaselect.com/142487/article" target="_blank" >http://www.eurekaselect.com/142487/article</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2174/0929867323666160525114026" target="_blank" >10.2174/0929867323666160525114026</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Adamantane - a lead structure for drugs in clinical practice
Popis výsledku v původním jazyce
The adamantane moiety is the structural backbone of numerous compounds and its discovery launched a new field of chemistry studying the approaches to the synthesis as well as the physicochemical and biological properties of organic polyhedral compounds with practical application in the pharmaceutical industry. Adamantane derivatives have proven to be very potent compounds in a wide range of applications from systemic to topical63 therapy. This review summarizes the currently available adamantane derivatives in clinical practice (amantadine, memantine, rimantadine, tromantadine, adapalene, saxagliptin, vildagliptin), focusing on mechanisms of action, pharmacokinetics, pharmacodynamics and clinical trials. The adamantane-based compounds presented in this manuscript have been approved for a wide spectrum of indications (antivirals, antidiabetics and against Alzheimer's and Parkinson's disease). Each of the compounds proved to be of vital importance in their therapeutic indication for numerous patients worldwide. This review also considers the mechanisms of side effects to deliver a complete perspective on current treatment options.
Název v anglickém jazyce
Adamantane - a lead structure for drugs in clinical practice
Popis výsledku anglicky
The adamantane moiety is the structural backbone of numerous compounds and its discovery launched a new field of chemistry studying the approaches to the synthesis as well as the physicochemical and biological properties of organic polyhedral compounds with practical application in the pharmaceutical industry. Adamantane derivatives have proven to be very potent compounds in a wide range of applications from systemic to topical63 therapy. This review summarizes the currently available adamantane derivatives in clinical practice (amantadine, memantine, rimantadine, tromantadine, adapalene, saxagliptin, vildagliptin), focusing on mechanisms of action, pharmacokinetics, pharmacodynamics and clinical trials. The adamantane-based compounds presented in this manuscript have been approved for a wide spectrum of indications (antivirals, antidiabetics and against Alzheimer's and Parkinson's disease). Each of the compounds proved to be of vital importance in their therapeutic indication for numerous patients worldwide. This review also considers the mechanisms of side effects to deliver a complete perspective on current treatment options.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FH - Neurologie, neurochirurgie, neurovědy
OECD FORD obor
—
Návaznosti výsledku
Projekt
Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2016
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Current Medicinal Chemistry
ISSN
0929-8673
e-ISSN
—
Svazek periodika
23
Číslo periodika v rámci svazku
29
Stát vydavatele periodika
NL - Nizozemsko
Počet stran výsledku
22
Strana od-do
3245-3266
Kód UT WoS článku
000387007800002
EID výsledku v databázi Scopus
2-s2.0-84996477477